APM
TCRT icon

Avidity Partners Management’s Alaunos Therapeutics TCRT Stock Holding History

Avidity Partners Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3,933
Closed -$643K – 108
2021
Q4 		$643K Sell
3,933
-16,067
-80% -$3.53M 0.01% 94
2021
Q3 		$5.46M Buy
+20,000
New +$6.12M 0.12% 82

Other funds holding TCRT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MP
MSD Partners New York $76.8M AUM 34.91% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Avidity Partners Management's TCRT Position: Q1 2022 in Review

Avidity Partners Management sold out of Alaunos Therapeutics (TCRT) in Q1 2022, closing a stake of 3,933 shares — an estimated $643K sold.

Avidity Partners Management first reported a position in TCRT in Q3 2021 and held it in 2 quarters. The position peaked at $5.46M in Q3 2021. 148 funds tracked by Wall St. Rank hold TCRT as of Q1 2022.

  • Avidity Partners Management reported no remaining Alaunos Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Avidity Partners Management sold 3,933 Alaunos Therapeutics shares in Q1 2022, an estimated $643K.
  • Avidity Partners Management first reported a position in Alaunos Therapeutics in Q3 2021 and held it in 2 quarters.
  • Avidity Partners Management's Alaunos Therapeutics position peaked at $5.46M in Q3 2021.
  • 148 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2022.

Based on Avidity Partners Management's 13F filing for Q1 2022, filed 16 May 2022.